Crescent Biopharma Inc. has announced a series of leadership appointments as it bolsters its team with experienced professionals in oncology drug development and biotech operations. Joshua Brumm has been named chief executive officer and joins the board of directors, while Jonathan McNeill, M.D., takes on the role of president and chief operating officer. Ellie Im, M.D., has been appointed chief medical officer, Rick Scalzo, MBA, as chief financial officer, Jan Pinkas, Ph.D., as chief scientific officer, Amy Reilly as chief communications officer, and Tanya Sengupta, MBA, as executive vice president, chief of strategy and operations. Additionally, David Lubner has joined the board of directors. These changes are part of Crescent's strategy to advance its therapeutic pipeline for solid tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.